AlphaCentric Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

AlphaCentric Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,000	Closed	-$615K	–	210
2024 Q3	$615K	Sell	40,000 -60,000	-60%	-$1M	0.46%	63
2024 Q2	$1.63M	Buy	100,000 +55,000	+122%	+$888K	1.2%	22
2024 Q1	$832K	Buy	45,000 +19,000	+73%	+$471K	0.5%	73
2023 Q4	$814K	Sell	26,000 -24,000	-48%	-$573K	0.55%	61
2023 Q3	$1.04M	Hold	50,000	–	–	0.59%	59
2023 Q2	$1.2M	Hold	50,000	–	–	0.66%	56
2023 Q1	$941K	Hold	50,000	–	–	0.65%	55
2022 Q4	$796K	Buy	+50,000	New	+$782K	0.79%	45
2021 Q4	$1.2M	Sell	51,500 -22,000	-30%	-$442K	0.35%	22
2021 Q3	$1.22M	Buy	73,500 +60,000	+444%	+$1.16M	0.31%	16
2021 Q2	$329K	Buy	+13,500	New	+$305K	0.09%	83
2021 Q1	–	Sell	-2,350	Closed	-$126K	–	207
2020 Q4	$126K	Sell	2,350 -800	-25%	-$39.7K	0.05%	98
2020 Q3	$130K	Buy	+3,150	New	+$136K	0.06%	62

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

AlphaCentric Advisors's ACAD Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 40,000 shares — an estimated $615K sold.

AlphaCentric Advisors first reported a position in ACAD in Q3 2020 and held it in 13 quarters. The position peaked at $1.63M in Q2 2024. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

AlphaCentric Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 40,000 Acadia Pharmaceuticals shares in Q4 2024, an estimated $615K.
AlphaCentric Advisors first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 13 quarters.
AlphaCentric Advisors's Acadia Pharmaceuticals position peaked at $1.63M in Q2 2024.
296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.